CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average recommendation of "Buy" from the twenty-two ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $158.13.
Several research analysts have weighed in on CRSP shares. Barclays raised their price objective on shares of CRISPR Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, April 21st. Citigroup raised CRISPR Therapeutics from a "sell" rating to a "neutral" rating and boosted their price objective for the company from $55.00 to $132.00 in a report on Monday, June 14th. Evercore ISI raised CRISPR Therapeutics to an "outperform" rating in a report on Thursday, May 13th. Jefferies Financial Group upgraded CRISPR Therapeutics from a "hold" rating to a "buy" rating and set a $172.00 price target for the company in a report on Wednesday, April 21st. Finally, Chardan Capital reissued a "buy" rating on shares of CRISPR Therapeutics in a research report on Wednesday, July 7th.
CRSP stock opened at $119.22 on Tuesday. The business's 50 day simple moving average is $128.88. CRISPR Therapeutics has a 52-week low of $76.71 and a 52-week high of $220.20. The stock has a market cap of $9.03 billion, a P/E ratio of -21.18 and a beta of 2.28.
CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, April 26th. The company reported ($1.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.04). The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $4.99 million. CRISPR Therapeutics had a negative return on equity of 27.42% and a negative net margin of 35,630.97%. As a group, research analysts anticipate that CRISPR Therapeutics will post 0.66 EPS for the current fiscal year.
In other news, President Rodger Novak sold 25,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, June 30th. The stock was sold at an average price of $165.00, for a total transaction of $4,125,000.00. Following the transaction, the president now directly owns 573,007 shares in the company, valued at approximately $94,546,155. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the firm's stock in a transaction dated Tuesday, June 15th. The shares were sold at an average price of $126.43, for a total value of $3,792,900.00. Following the transaction, the chief executive officer now directly owns 217,719 shares of the company's stock, valued at approximately $27,526,213.17. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,375 shares of company stock valued at $16,770,580. 21.40% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of CRSP. CloudAlpha Capital Management Limited Hong Kong acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $459,000. Koshinski Asset Management Inc. purchased a new stake in CRISPR Therapeutics during the fourth quarter valued at about $278,000. FIL Ltd boosted its holdings in shares of CRISPR Therapeutics by 69,066.2% in the fourth quarter. FIL Ltd now owns 53,258 shares of the company's stock worth $8,154,000 after buying an additional 53,181 shares during the period. Northern Trust Corp increased its position in shares of CRISPR Therapeutics by 5.5% in the fourth quarter. Northern Trust Corp now owns 47,913 shares of the company's stock worth $7,336,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in shares of CRISPR Therapeutics by 33.0% in the fourth quarter. Stifel Financial Corp now owns 16,801 shares of the company's stock valued at $2,572,000 after purchasing an additional 4,166 shares in the last quarter. Hedge funds and other institutional investors own 55.43% of the company's stock.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Featured Article: Systematic Risk
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is the float in trading stocks?
Bellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.
The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.
But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.
With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.
One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.